BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
9.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MTech Mobility Appoints Rodney Moore as General Manager, Europe, to Accelerate Regional Growth15.9.2026 12:00:00 CEST | Press release
Seasoned technology executive brings more than 30 years of enterprise IT leadership to Dublin as MTech Mobility deepens its European commitment following Aer Lingus implementation win DUBLIN, IRELAND / ACCESS Newswire / September 15, 2026 / MTech Mobility today announced the appointment of Rodney Moore as General Manager, Europe. Moore, based in Dublin, will lead MTech Mobility's European operations, expand the regional team, and serve as the primary point of contact for the company's growing base of European customers. "Our European customers face challenges that demand more than a remote relationship - they need a partner who is present, accountable, and embedded in their landscape. Rodney's appointment is a direct investment in that commitment. His track record across Ireland and the UK means he understands exactly what European enterprises face, and he has the depth of experience to help them solve it. We are not just expanding our footprint; we are building the kind of trusted par
Chervon Names Matthew H. DeFeo as Senior Vice President of Sales, Training and Recruiting15.9.2026 00:00:00 CEST | Press release
Accomplished Power Tools and Outdoor Power Equipment industry leader brings decades of experience in sales leadership, talent recruitment and development, channel management, and key account alignment NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / Matthew DeFeo joins Chervon as Senior Vice President of Sales, Training, and Recruiting effective September 14, 2026, reporting to CEO Joe Galli. Matthew DeFeo brings more than four decades of experience in the power tool and outdoor power equipment industry. He has an exceptional track record in building and leading large sales organizations, channel marketing teams, and training and development teams. DeFeo is widely recognized as a world-class leader in the campus recruiting of high potential graduates. He has built out impressive in-store sales coverage teams, end user marketing teams, campus recruiting teams, and training teams with an intense focus on key account alignment. A hallmark of DeFeo's remarkable career is his mentors
Chervon Names Jeffrey P. Campbell Senior Vice President of Industrial Commercial Sales14.9.2026 23:50:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / Jeffrey P. Campbell joins Chervon as Senior Vice President of Industrial Commercial Sales effective Monday, September 14, 2026, reporting to CEO Joe Galli. Campbell joins Chervon with 25 years of exceptional executive leadership experience in the professional tool industry. He has built and led high-performance sales and channel marketing teams, developed strategic key account partnerships and has consistently driven strong growth across all professional and automotive channels of distribution. In his new role, Campbell will lead Chervon's Industrial / Commercial Sales network serving the many professional and automotive tool channels. "Jeff brings an impressive and unmatched combination of professional and automotive channel sales leadership, channel management, customer partnership skills and organizational development," said Joe Galli, CEO of Chervon. "His exhaustive command of our channels, key accounts, and users, combined wi
AGFA HealthCare Puts Clinical Attention at the Center of Enterprise Imaging at RSNA 202614.9.2026 16:30:00 CEST | Press release
One unified Enterprise Imaging platform brings workflow, streaming, cloud, and AI together to help clinicians stay focused and imaging organizations reduce complexity. CARLSTADT, NJ / ACCESS Newswire / September 14, 2026 / "Clinical attention has become one of healthcare's most valuable resources. The technology surrounding clinicians should preserve focus, not compete for it," said Nathalie McCaughley, President, AGFA HealthCare. "At RSNA 2026, we're showing how Enterprise Imaging continues to evolve around one consistent clinical experience. By bringing workflow, intelligence, and information together around how clinicians naturally work, we can reduce friction and help keep clinical attention where it matters most." At RSNA 2026, AGFA HealthCare will demonstrate how a unified approach to Enterprise Imaging can help healthcare organizations address a growing challenge: imaging volumes and clinical complexity continue to increase, while radiologists and imaging teams are being asked t
Litum Expands PathAware from Collision Warning to Forklift Safety Intelligence14.9.2026 08:00:00 CEST | Press release
PathAware® now turns collision risks, near misses and operator activity into actionable safety intelligence, while adding operator control, digital inspections and utilization insights, all through a retrofit system built for mixed forklift fleets. BOSTON, MA / ACCESS Newswire / September 14, 2026 / Litum today announced PathAware® IQ and PathAware® IQ+, expanding its forklift collision warning technology into a connected safety intelligence platform. PathAware IQ not only warns operators when risks occur. It captures safety events across the fleet and turns them into visual dashboards and actionable data, giving safety teams visibility into recurring risks, near misses, operators, vehicles, areas and shifts. This allows organizations to move from reacting to incidents to identifying patterns earlier, targeting operator training, addressing recurring hazards and measuring whether safety actions are actually working. PathAware IQ+ builds on that intelligence with digital pre-operation i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom